Effectiveness and costs of chemical versus electrical cardioversion of atrial fibrillation

dc.contributor.authorPaola, Angelo Amato Vincenzo de [UNIFESP]
dc.contributor.authorFigueiredo, Edilberto [UNIFESP]
dc.contributor.authorSesso, Ricardo [UNIFESP]
dc.contributor.authorVeloso, Henrique Horta [UNIFESP]
dc.contributor.authorNascimento, Luiz Olympio T [UNIFESP]
dc.contributor.authorSOCESP Inv
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.date.accessioned2016-01-24T12:33:46Z
dc.date.available2016-01-24T12:33:46Z
dc.date.issued2003-04-01
dc.description.abstractBackground: Atrial fibrillation is the most common sustained cardiac arrhythmia and has an important impact on costs of medical assistance. Traditional interventions to convert atrial fibrillation to sinus rhythm are antiarrhythmic drugs and external electrical cardioversion. However, the best option for starting the cardioversion is not well established. Methods: in a multicentre randomised trial of 139 patients with persistent atrial fibrillation lasting less than 6 months, we compared the effectiveness and the cost-effectiveness ratio of initial treatment with chemical or electrical cardioversion. Subjects who did not achieve sinus rhythm with chemical cardioversion were considered to undergo electrical cardioversion and vice-versa. Results: the efficacy of the initial attempt for cardioversion was similar with chemical or electrical cardioversion (74 vs. 73%, P = 0.95). However, the strategy of starting with antiarrhythmic drugs was more effective than with electrical procedure (96 vs. 84%, P = 0.0016). Initiating with chemical cardioversion was also less expensive than with electrical cardioversion (US$1240 vs. US$1917; P = 0.002). Life-threatening complications occurred only during chemical cardioversion (5%), all of them in patients with structural heart disease. Conclusions: in patients with persistent atrial fibrillation of less than 6 months, initial chemical or electrical cardioversion appear to be similar but the strategy of starting the cardioversion with antiarrhythmic drugs is more effective and less expensive than starting with the electrical procedure. Patients with structural heart disease undergoing chemical cardioversion seem to be more susceptible to severe complications. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.en
dc.description.affiliationUniversidade Federal de São Paulo, Paulista Sch Med, BR-04024002 São Paulo, Brazil
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Paulista Sch Med, BR-04024002 São Paulo, Brazil
dc.description.sourceWeb of Science
dc.format.extent157-166
dc.identifierhttp://dx.doi.org/10.1016/S0167-5273(02)00380-7
dc.identifier.citationInternational Journal of Cardiology. Clare: Elsevier Sci Ireland Ltd, v. 88, n. 2-3, p. 157-166, 2003.
dc.identifier.doi10.1016/S0167-5273(02)00380-7
dc.identifier.issn0167-5273
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/27189
dc.identifier.wosWOS:000183117500007
dc.language.isoeng
dc.publisherElsevier B.V.
dc.relation.ispartofInternational Journal of Cardiology
dc.rightsAcesso restrito
dc.rights.licensehttp://www.elsevier.com/about/open-access/open-access-policies/article-posting-policy
dc.subjectatrial fibrillationen
dc.subjectcost-effectivenessen
dc.subjectelectrical cardioversionen
dc.subjectantiarrhythmic drugen
dc.subjectcardiac arrhythmiaen
dc.titleEffectiveness and costs of chemical versus electrical cardioversion of atrial fibrillationen
dc.typeArtigo
Arquivos
Coleções